Belrestotug

贝瑞苏塔单抗

Report date: 2025/05/24 20:00:06

Base Information

Drug NameBelrestotug
Drug Alias NameEOS-448EOS-884448GSK-4428859GSK-4428859A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesIteos
China Registration ClassN/A

Develop Information

Active CompaniesITeos Therapeutics IncGlaxosmithkline Plc
Inactive CompaniesGlaxosmithkline Research & Development LtdGlaxo Operations Uk LtdiTeos Belgium SA +[4] 
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursLung NeoplasmsHead and Neck Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A